Study Comparing Olaparib and Chemotherapy for Patients with Recurrent Ovarian Cancer After Surgery

1 1 1 1

What is this study about?

This clinical trial is focused on studying the effects of a medication called olaparib in patients with recurrent ovarian cancer. The study compares the use of olaparib, which is taken as a tablet, to standard chemotherapy treatments that include medications such as paclitaxel, carboplatin, gemcitabine, doxorubicin, bevacizumab, and cisplatin. These chemotherapy drugs are typically given through an intravenous (IV) infusion.

The purpose of the study is to determine how effective olaparib is in maintaining the health of patients after their cancer has progressed, compared to the standard chemotherapy options. Participants in the study will receive either olaparib or one of the standard chemotherapy treatments after undergoing a surgical procedure known as secondary cytoreductive surgery, which aims to remove as much of the cancer as possible.

The study will follow participants over a period of time to observe their progression-free survival, which means the length of time during and after treatment that a patient lives with the disease without it getting worse. The study will also look at overall survival, safety, and quality of life. Participants will be randomly assigned to receive either olaparib or one of the standard chemotherapy treatments, and some may receive a placebo. The study is designed to provide valuable information on the best treatment options for patients with recurrent ovarian cancer.

1 initiation of treatment

Upon joining the study, the patient will begin treatment with olaparib in the form of film-coated tablets. The dosage will be either 150 mg or 100 mg, taken orally. The specific dosage and frequency will be determined by the study protocol and the patient’s condition.

2 chemotherapy administration

The patient may receive chemotherapy drugs such as paclitaxel, carboplatin, gemcitabine hydrochloride, doxorubicin hydrochloride, bevacizumab, and cisplatin. These medications are administered intravenously, meaning they are given through a vein. The specific drugs and their dosages will be determined based on the patient’s treatment plan.

3 monitoring and follow-up

Throughout the trial, the patient’s health and response to treatment will be closely monitored. This includes regular check-ups and tests to assess the effectiveness of the treatment and to identify any side effects. The frequency and type of monitoring will be specified in the study protocol.

4 completion of treatment

The treatment phase will continue until the study’s end date or until the patient completes the prescribed course of treatment. The estimated end date for the trial is December 31, 2026. Upon completion, the patient’s overall health and treatment outcomes will be evaluated.

Who Can Join the Study?

Must sign a form agreeing to participate in the study.
Must be a female who is at least 18 years old.
Must have a type of cancer called high-grade serous or endometroid ovarian, fallopian tube, or primary peritoneal cancer that has come back or is getting worse after initial treatment.
Must have had only one previous treatment with a platinum-containing regimen (a type of chemotherapy). Treatments with a drug called bevacizumab are allowed.
Must have received a first-line maintenance therapy with a PARPi (a type of medication) for at least 6 months. If the medication used was olaparib, it should not have caused serious side effects or required a permanent dose reduction.
Must have had surgery to remove cancer that has come back. The surgery should have removed all visible cancer or at least the cancer that was growing during maintenance therapy.
Must have a known BRCA1/2 status (genes related to cancer risk). If the status is unknown, must agree to have it tested before joining the study.
Must have a life expectancy of at least 16 weeks.
Must start the study treatments within 3 to 8 weeks after the second surgery.
Must have an ECOG performance status of 0 to 1, which means being fully active or having some symptoms but still able to carry out light work.
Must provide samples from both the first and second surgeries for analysis.
Must be able to take medications by mouth.
Must have normal organ and bone marrow function, which includes:
- Hemoglobin level of at least 10.0 g/dL without a blood transfusion in the past 28 days.
- Absolute neutrophil count (ANC) of at least 1.5 x 10⁹/L.
- Platelet count of at least 100 x 10⁹/L.
- Total bilirubin level of no more than 1.5 times the normal limit.
- AST and ALT levels of no more than 2.5 times the normal limit (or 5 times if there are liver metastases).
- Creatinine clearance of at least 51 mL/min, which measures kidney function.
- If not on blood thinners, INR or aPTT should be no more than 1.5 times the normal limit. If on blood thinners, specific ranges apply.
Must be postmenopausal or have proof of not being able to have children, confirmed by a negative pregnancy test before starting the study.

Who Cannot Join the Study?

Patients who have not undergone secondary cytoreductive surgery for their recurrent or progressive ovarian cancer. This is a surgery to remove as much of the cancer as possible after it has returned or continued to grow.
Patients who are not female, as the study is only for women.
Patients who are part of a vulnerable population, meaning those who might need special protection or care, are not included in this study.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country
Ente Ecclesiastico Ospedale Generale Regionale Miulli	Acquaviva Delle Fonti	Italy
Azienda Ospedaliero Universitaria Careggi	Florence	Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS	Rome	Italy
Azienda Ospedaliera Universitaria Universita’ Degli Studi Della Campania Luigi Vanvitelli	Naples	Italy
Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari	Bari	Italy
Azienda Ospedaliera Universitaria Federico II Di Napoli	Naples	Italy
Azienda Ospedaliero Universitaria Di Sassari	Sassari	Italy

Other Sites

Site Name	City	Country
Istituto Oncologico Veneto	Padua	Italy
Ospedale Vito Fazzi Lecce	Lecce	Italy
Centro Di Riferimento Oncologico Di Aviano	Aviano	Italy
IRCCS Istituto Nazionale Tumori Fondazione Pascale	Naples	Italy
Azienda Unita Locale Socio Sanitaria N 8 Berica	Vicenza	Italy
ARNAS Civico Di Cristina Benfratelli	Palermo	Italy
Azienda Ospedaliera Ordine Mauriziano Di Torino	Turin	Italy
Azienda Unita’ Locale Socio Sanitaria N. 2 Marca Trevigiana	Treviso	Italy
Azienda Sanitaria Locale Al Di Alessandria	Alexandria	Italy
Ospedale S G Moscati	Statte	Italy
Ospedale San Raffaele S.r.l.	Milan	Italy
Universita’ Degli Studi Di Verona	Verona	Italy
Istituto Di Candiolo Fondazione Del Piemonte Per Loncologia IRCCS	Candiolo	Italy
Alessandro Manzoni Hospital	Lecco	Italy
Azienda Ospedaliero-Universitaria Maggiore Della Carita	Novara	Italy
Azienda USL Toscana Sud Est	Arezzo	Italy
Azienda Unita Sanitaria Locale Della Romagna	Faenza	Italy
Azienda Provinciale Per I Servizi Sanitari	Trento	Italy
Universita’ Di Pisa	Pisa	Italy
Hlwopgnsg Mxhtgqzo Sgdlsx	Milan	Italy
Aymxqsl Orhzspyokds Urjtlaioizqxq Pnklj	Parma	Italy
Osfnsyyq Srjuz Mtxxq Drrcu Mtrquzapcqhz &joqaiq Aurvjgl Oreyktudwxt dd Pfhlore	Perugia	Italy
Icozb Iypilxbk Fwhfjwbmapoeu Oztxtqtzpxio Inbfzjwz Nooemlnpz tpkbcx Rgslcd Eafeg	Rome	Italy
Osmgipod Srylx Mkzfk dhphc Mqrzfvaudogk	Udine	Italy
Odezckrv Gkxdxukbv	Catania	Italy
Iylkykab Rzyxmawox Puh Ln Sjhove Dof Ttakba Dbpa Almucqv Ioan Siwdhd	Meldola	Italy
Akodihu Ogoluprengb Prc Lnkzzfeignqluuwjv Cwwefyjbol	Catania	Italy
Axpovwt Uow Iivcf Da Rjfmhd Erucvt	Reggio Emilia	Italy
Anmwgcp Ukjfs Sgfityqvn Lazicv Ds Beghnyk	Bologna	Italy
Umduwfzgst Mjozs Gyduiuu Oz Czprvtcab	Catanzaro	Italy
Airldnu Sbcch Sacvlycrs Tesyoiccujel Rxrldnla	Rho	Italy

Trial status

Country	Status	Recruitment Start
Italy	Recruiting	22.03.2023

Trial locations

Investigated drugs:

Olaparib is a medication used in this trial to see if it can help patients with recurrent ovarian cancer live longer without the disease getting worse. It is being tested to see if it works better than the usual chemotherapy after patients have had surgery to remove as much of the cancer as possible. Olaparib is a type of targeted therapy known as a PARP inhibitor, which works by preventing cancer cells from repairing themselves, leading to their death.

Investigated diseases:

Ovarian cancer recurrent

Recurrent Ovarian Cancer – This disease occurs when ovarian cancer returns after a period of remission. It typically involves the reappearance of cancerous cells in the ovaries or other areas of the body after initial treatment. The progression of recurrent ovarian cancer can vary, with some patients experiencing slow growth of cancer cells, while others may have a more rapid progression. Symptoms may include abdominal pain, bloating, and changes in bowel habits. The disease often requires further medical intervention to manage its progression.

Trial ID:

2024-516842-21-00

NCT ID:

NCT05255471

Trial Phase:

Therapeutic confirmatory (Phase III)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study Comparing Olaparib and Chemotherapy for Patients with Recurrent Ovarian Cancer After Surgery

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?